Gilead Sciences, Inc.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Shares of Gilead Sciences are jumping in aftermarket trading following full approval for Veklury (remdesivir) as a treatment for COVID-19. The approval marks the first drug approved by the U.S. Food and Drug Administration as a treatment for the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
It was a moderately busy week for clinical trial news. Here’s a look.
The U.S. National Institutes of Health (NIH) is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
The company allegedly used a foundation as a conduit to pay the copays of Medicare patients who were taking Letairis, Gilead’s pulmonary arterial hypertension drug.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 2, 2020.
The deal, announced Sunday, has been unanimously approved by the boards of directors of both companies.
Gilead Sciences and Jounce Therapeutics entered a discovery and development deal to exclusively license Jounce’s JTX-1811 immuno-oncology program.
JOBS
IN THE PRESS